FR2692147A1 - Bioresorbable polymer microspheres free of surfactant, their preparation and their application as medicaments. - Google Patents

Abstract

Microspheres consisting of a polymer matrix and optionally at least one active substance encapsulated in said polymer matrix made from at least one hydroxyacid polymer or copolymer. Said microspheres are characterized by the absence of surface active agents and of constituents other than the optionally present active substance and the polymer constituents. The microspheres can be obtained by using, as the polymer matrix, a poly(hydroxyacid) of high molecular weight exceeding 20,000 and a poly(hydroxyacid) having a molecular weight of less than 5,000. The incorporation of said microspheres as drugs is beneficial in preventing the induced toxicity associated with microspheres of the past caused by the residual surface active agent.

Description

 The invention relates to novel microspheres in bioresorbable polymer, surfactant exampés, their preparation and their application.

 The encapsulation of active substances in polymer matrices, in order to protect these active substances or to release them gradually, is well known.

 Various systems are known, also called delayed effect systems, which gradually release into the organism where they are implanted pharmacologically active principles of therapeutic interest which are dispersed in a polymer matrix. The polymers used may be derived from natural polymers (cellulose or proteins), or may be synthetic polymers.

 Bioresorbable polymers, ie polymers that are progressively degraded in the body and whose degradation products are eliminated by metabolization or excretion, are among the materials that can be implanted in the body. interesting, especially because they make unnecessary surgery to remove the implant at the end of its operating period. This is the case of polyesters derived from hydroxy acids. These polyesters are also abbreviated as poly (hydroxy acids).

 Bioresorbable and progressive release systems may also be in the form of microspheres that can be administered orally, intramuscularly, or intravenously.

 By microsphere is meant a solid spherical system whose average diameter does not exceed a few hundred micrometers (in particular 500 lux), this concept including spheres (sometimes called nanospheres) with a mean diameter of less than one micrometer.

 The main advantage of the microspheres is that they can easily administer by injection of the active ingredients having a long duration of action through their gradual release, which improves the therapeutic action of these active ingredients and reduces their potential toxicity. This method avoids the placement of implants that can be the source of inflammation or infections. It also avoids repeated administrations since the action of the active ingredient is done over a longer period.

 The microspheres that do not contain an active ingredient also have therapeutic utility: they can be used in particular to cause the embolization of angiomas.

 The microspheres can be obtained by various techniques, in particular according to the method known as solvent evaporation. This method can be described as follows: the active ingredient to be encapsulated and the polymer which constitutes the microspheres are dissolved in a volatile organic solvent immiscible with water. The resulting solution is emulsified with a surfactant. The progressive evaporation of the organic solvent leads to the transformation of the droplets of the emulsion into solid microspheres in which the active ingredient is trapped.

 This technique therefore involves a surfactant whose function is to promote the stability of the emulsion and thus to ensure the correct formation of the microspheres and the stability of the suspensions thereof in liquid injection media.

 However, the presence of a surfactant on the surface of the microspheres, in an organism, is likely to modify the characteristics and the performances of the delay system and even render it unusable if the surfactant is toxic, or if it is strongly attached to the surface, because it modifies the interface organism / synthetic polymer material, It is indeed this interface that conditions the release of the active ingredient and the response of the implantation medium.

 One of the most suitable surfactants for the manufacture of polymer-based microparticles is polyvinyl alcohol (PVA), which gives rise to the formation of very few particle agglomerates and which makes it possible to easily obtain microspheres of a large size. less than 1501lu. However, the use of PVA raises potential toxicity issues. Indeed, this compound is considered to be potentially carcinogenic, in particular when it is administered parenterally.

 Thus, the use of any surfactant during the preparation of the microspheres by solvent evaporation is likely to modify the characteristics of the delay system. The morphology of the microspheres (size, shape, presence of surfactant on the surface) but also the efficiency of the system both for the incorporation of the active substance and for the release, are influenced by the surfactant.

 It has now been discovered that it is possible to obtain microspheres whose only constituents, in addition to the encapsulated active substance, are those of the polymer matrix, and which can be prepared without resorting to the addition of conventional surfactants. In addition, the microspheres obtained give stable suspensions.

The invention therefore relates to microspheres consisting of a polymer matrix and optionally at least one active substance encapsulated in said polymer matrix made of at least one hydroxy acid polymer or copolymer, characterized in that said microspheres are free of of constituents other than the active substance (when present) and the constituents of the polymer. In other words, the microspheres of the invention do not contain a surfactant,
It has in fact been found that it is possible to obtain microspheres having satisfactory characteristics, without using surfactants, by using mixtures of poly (hydroxy acids), of high molecular weight and of low molecular weight, as will be specified here. -after.

 Poly (hydroxy acid) is a polyester whose structure results from the esterification of the hydroxyl group of a hydroxy acid molecule by another molecule of hydroxy acid, and so on. It is a homopolymer or a copolymer.

 The microspheres of the invention can be characterized both by the absence of surfactants and by a (at least) bimodal distribution of the molecular weights of the constituents of the polymer matrix.

 The microspheres of the invention, the polymer matrix of which consists essentially of at least one hydroxy acid polymer or copolymer, may be prepared by a process in which said polymer or copolymer is dissolved in a volatile liquid organic phase which is immiscible with water. water, optionally dissolving or dispersing an active substance in said organic phase, preparing an emulsion of the organic phase obtained in an aqueous continuous phase, evaporating the solvent and separating, if desired, the solid microspheres obtained from the aqueous phase, this method being characterized in that said polymer or copolymer comprises at least one poly (hydroxy acid) of average molecular weight at least 20,000, and at least one poly (hydroxy acid) of average molecular mass less than 5,000, which after the realization of the emulsion, the pH is adjusted to a value of 6-8 by addition of a base, and during the evaporation step of the organic solvent, the pH is adjusted to 6-8 by continuous addition or by repeated addition of a base.

 As a base, for example, sodium or potassium hydroxide, or an amine such as triethylamine, is used.

 Of course, the water can be replaced by any other liquid in which the volatile organic phase is not soluble.

 Among the polymers constituting the matrix of the microspheres of the invention, mention may be made, for example, of poly (alpha-hydroxy acids), poly (beta-hydroxy acids), for example poly (beta-hydroxybutyrate), or polymers of monoesterified malic acid. such as poly (benzyl malate) or polymers of other hydroxy acids, such as poly (-caprolactone), and their copolymers. Among the preferred polymers, mention will be made more particularly of poly (alpha-hydroxy acids) such as poly (lactic acid), poly (glycolic acid), and their copolymers. It is known that these polymers are linear polyesters containing repeating units of the formula: - [O-CH (R) -COI-, in which R represents H in the case of poly (glycolic acid) and R represents -CH3 in the case poly (lactic acid).

 It is also possible to use copolymers (polyesters) derived from these hydroxy acids, for example copolymers of the poly (lactic-co-glycolic acid) type which contain repeating units and - [O-CH (CH 3) -CO-] p and EOCH 2 CO 2. p and q being the molar proportions of the lactic and glycolic units, respectively.

 Preferably, the polymers used are amorphous, or at least partially amorphous.

The poly (hydroxy acids) of average molecular weight at least 20,000, and in particular at least 40,000, are known products or can be prepared according to known methods. Some of them are also commercial products. For example, to prepare a poly (lactic acid) of high average molecular weight, or a lactic-glycolic copolymer, ring opening of cyclic diesters (lactide, glycolide or mixtures thereof) can be carried out according to the usual methods. In the case of lactic acid, which exists in the optically active forms D and L, a mixture of these two forms containing, for example, a sufficient quantity of units, is preferably used.
D-lactics so that the polymer obtained is amorphous.Un particular will be used a starting material consisting of a mixture of D- and L-lactides chosen so that the proportion of patterns
D-lactics is sufficient for the polymer obtained to be amorphous. This proportion can easily be determined in each case by simple routine experiments. Most often we will use polymers containing from 30 to 70% of units derived from the acid
D-lactic, and in particular 50%.

Poly (hydroxy acids) of low average molecular weight, less than 5000, are also known products, some of which are commercially available, or can be prepared according to known methods. For example, to prepare a poly (lactic acid) of low average molecular weight, it is possible to operate by polycondensation of acid mixtures.
L- and D-lactics, in particular by polycondensation of D-, L-lactic acid. Corresponding copolymers are prepared analogously.

The molecular weights of the polymers used according to the invention can be determined, for example, in solution, by gel permeation chromatography, in comparison with standard polymers, in particular polystyrene standards;
Molecular weights are molecular weights in number or weight. For example, the lower limit of 20,000 for the high molecular weight (MM) polymer is a number MM, and the maximum value of 5000 for the low MM polymer is a
MM by weight.

 Preferably, polymers whose polydispersity index is not more than about 3, and in particular less than 2, are used.

 The organic phase used in the process of the invention mainly comprises an organic solvent, immiscible with water, or very slightly soluble in water, such as chloroform, dichloromethane, etc.

 This organic phase contains in the dissolved state the high molecular weight polymer, at least 20,000, and the low molecular weight polymer, less than 5,000.

 The proportions of low molecular weight polymer, relative to the high molecular weight polymer, are the proportions which make it possible to obtain microspheres of sufficient quality (in particular a satisfactory surface state), and having the desired particle sizes (in particular sufficiently low), with acceptable performance. These proportions can be determined in each case by simple routine experiments.

Generally, a proportion of 30 to 300%, and particularly 50% to 150% by weight of low molecular weight polymer, based on the weight of high molecular weight polymer can be used. The increase in the proportion of low molecular weight polymer makes it possible to obtain a reduction in the size of the particles.

 The organic phase may further contain an active substance, which may be added before or after the addition of the polymers; the active substance may be chosen especially from steroid hormones or their synthetic analogues (for example progesterone, norgestrel, estradiol, norethisterone, testosterone, hydrocortisone, prednisolone, dexamethasone), anti-cancer agents (doxorubicin, bleomycin, cis-platinum, -fluoro-uracil), narcotic antagonists (eg Naltrexone), neurosedatives or anesthetics (phenobarbitone, chlorpromazine, methadone, diazepam), antibiotics (erythromycin, gentamycin), etc.

 Preferably, the active substance is a lipophilic substance, so as to facilitate its incorporation into the microspheres.

 An emulsion is then produced by progressively pouring, with stirring, the organic phase in a suitable quantity of water. The amount of water can be determined, for example, so as to use the minimum amount of water, to limit the diffusion of the active ingredient (when it is present) in the aqueous phase, however, the amount of water must be sufficient to that the shape of the microspheres is as regular as possible. The amount of water can therefore be determined in each case by simple routine experiments.

 When it is desired to obtain nanoparticles, the emulsion can be subjected to the action of ultrasound or a homogenizer so as to increase the state of division of the emulsion. The ultrasound is applied or homogenized for a time sufficient for the microdroplets of the emulsion to reach a sufficiently small, predetermined size. Here again, the development of the process can be carried out by simple routine experiments.

 After completion of the emulsion, the pH is adjusted to a value of 6-8, in particular 7-8, by addition of a base such as sodium or potassium hydroxide or trimethylamine, since the partial dissolution polyacids of low molecular weight give the water an acidic pH. It is therefore important to adjust the pH to a level sufficient for the carboxylic groups, in the aqueous phase or in contact with it, to be in the carboxylate form which is necessary for the microspheres to be stabilized.

 It is undesirable for the aqueous phase to be brought to a pH of 7-8 from the beginning of the emulsion production, since it would then be necessary to fear that the low molecular weight polymers will associate to form micelles. in the aqueous phase.

 The organic solvent is then evaporated at a temperature that can range, for example, from 0 ° to 40 ° C. This operation can be facilitated by operating under reduced pressure.

 During the evaporation step of the organic solvent, the pH is adjusted to a sufficient value, for example 6-8, in particular 7-8, for the reasons already indicated above, by means of continuous addition or by repeated additions of a base such as those mentioned above.

 Of course, during the evaporation step, appropriate stirring of the emulsion is maintained.

 After the evaporation step of the organic solvent, the microspheres can be recovered, for example by centrifugation or filtration. They can then be dried and optionally sieved.

 The microspheres according to the invention can be used according to the known methods. In particular, when the incorporated active substance is a drug, the microspheres can be used orally, in the form of powders, aqueous suspensions or capsules. When the microspheres have a sufficiently small size, for example less than 150 μm, they can be administered by injection, according to known methods. In addition, as indicated above, microspheres possibly containing no active substance can be injected so as to locally cause embolization of the angioma vascularization system.

 The subject of the invention is also a medicament based on microspheres as defined above.

 The following examples illustrate the invention.

EXAMPLE 1
A) Polymer preparation
a) A D-, L-lactic acid / glycolic acid copolymer containing 25% units derived from glycolic acid was prepared as follows:
78.83 g of D, L-lactide and 21.17 g of glycolide are mixed to form 100 g of the polymerizable monomer mixture. 0.025% by weight of antimony trifluoride is added.

The mixture is degassed by repeated cycles of vacuum and nitrogen. After sealing under vacuum, the polymerization is carried out in bulk at 1600 ° C. for 3 days.

 The number-average molecular weight of the copolymer, determined by gel permeation chromatography, compared with polystyrene standards, is 38,000. The polymolecularity index (I) is: 1.6.

 (b) Low molecular weight poly (lactic acid) was prepared by polycondensation of D-Lactic acid at 140 ° C under vacuum for three days The reaction product was cooled and dissolved in acetone. water to the solution so as to precipitate the polymer, while the residual monomers remain in solution The polymer is then dried under vacuum.

 Its weight-average molecular weight, determined by gel permeation chromatography, is 2500, relative to polystyrene standards; I = 1.5.

B) Preparation of microspheres
3.8 g of the copolymer and 1.2 g of the poly (lactic acid) are dissolved in 50 ml of dichloromethane.

 The solution obtained is gradually poured in with stirring into 1250 ml of distilled water. The pH, initially of 5-6, drops rapidly to 3. After about one minute after the end of the addition of the organic phase, a 0.2N aqueous solution of sodium hydroxide is added so as to reduce the pH to 7. , About 5. Then the evaporation step of the organic solvent, by natural volatilization at room temperature for 4 hours, with stirring.

 While maintaining stirring, 0.2N sodium hydroxide is periodically added during the evaporation phase to bring the pH back above 7. As the dichloromethane evaporates, the pH decreases less rapidly and the end of the operation, it stabilizes around 7.

 The microspheres obtained are then collected by filtration and dried under reduced pressure.

 To study the size distribution of the microspheres, sieves having mesh sizes of 500, 250, 125, 100 and 80 μm respectively are used. Particles larger than 500 μm are removed. The amounts of microspheres recovered in each sieve were weighed.

The results are summarized in the following Table I:
TABLE I

<tb> Diameter <SEP> Ko <SEP> in <SEP> weight
<tb><SEP> Lm
<tb> between <SEP> 250 <SEP> and <SEP> 500 <SEP> 25.6
<tb> between <SEP> 125 <SEP> and <SEP> 250 <SEP> 45.2
<tb> between <SEP> 100 <SEP> and <SEP> 125 <SEP> 16.8
<tb> between <SEP> 80 <SEP> and <SEP> 100 <SEP> i <SEP> 7.5
<tb> c80 <SEP> 4.9
<Tb>
In optical microscopy, the microspheres have a substantially spherical shape and a regular surface.

 These results were confirmed by scanning electron microscopy. The very regular surface state of the microspheres is comparable to that of the microspheres obtained by using polyvinyl alcohol as a surfactant.

EXAMPLE 2
The procedure is analogous to that described in Example 1, but using equal parts (by weight) of the copolymer and poly (lactic acid) of low molecular weight.

 Microspheres with a diameter less than 500 RM are obtained with a yield of 61%. Particles smaller than 45 .mu.m are separated.

The results are summarized in the following Table II
TABLE II

<tb><SEP> Diameter <SEP>% <SEP> in <SEP> weight
<tb><SEP> Cun
<tb><SEP> between <SEP> 250 <SEP> and <SEP> 500 <SEP> 6.04
<tb><SEP> between <SEP> 125 <SEP> and <SEP> 250 <SEP> 5.56
<tb><SEP> between <SEP> 100 <SEP> and <SEP> 125 <SEP> 7.03
<tb><SEP> between <SEP> 80 <SEP> and <SEP> 100 <SEP> 27.19
<tb><SEP> between <SEP> 45 <SEP> and <SEP> 80 <SEP> 48.50
<tb><45<SEP> 5.68
<Tb>
EXAMPLE 3
1 g of copolymer obtained in Example 1 (A, a) and 1 g of low molecular weight poly (lactic acid) obtained in Example 1 (A, b) and 0.25 g of progesterone are dissolved in 20 ml of dichromethane.

 The solution obtained is gradually poured into the solution obtained in 500 ml of distilled water. The pH drops rapidly to 3. After about one minute after the end of the addition of the organic phase, the pH is brought to 7.5 by addition of 0.2N sodium hydroxide. The operation is then carried out as described in Example 1.

 Microspheres in which progesterone is incorporated are obtained.

Claims (10)

 1. Microspheres consisting of a polymer matrix and optionally at least one active substance encapsulated in said polymer matrix made of at least one hydroxy acid polymer or copolymer, characterized in that they are free of constituents other than the substance optionally present active and the constituents of the polymer.  2. Microspheres according to claim 1 or 2, characterized in that the component of the polymer matrix has a bimodal molecular weight distribution.  Microspheres according to any one of the preceding claims, characterized in that the polymer matrix contains at least one poly (hydroxy acid) having a molecular mass greater than 20,000, and in particular greater than 40,000, and at least one poly ( hydroxy acid) having a molecular weight of less than 5000.  4. Microspheres according to any one of the preceding claims, characterized in that they have dimensions less than 500 KLm.  5. Process for the preparation of microspheres as defined in any one of the preceding claims, in which said polymer or copolymer is dissolved in a volatile organic liquid phase immiscible with water, an active substance is optionally solubilized or dispersed in said organic phase, an emulsion of the organic phase obtained is prepared in an aqueous continuous phase, the solvent is evaporated and, if desired, the solid microspheres obtained are separated from the aqueous phase, characterized in that the said polymer or copolymer comprises at least one poly (hydroxy acid) of average molecular weight at least 20,000 and at least one poly (hydroxy acid) of average molecular weight less than 5,000, after the emulsion is made, the pH is adjusted to a value of 6 -8 by addition of a strong base, and during the evaporation step of the organic solvent, the pH is adjusted to a value of 6-8 by continuous addition or by repeated additions of a base.  6. Process according to the preceding claim, characterized in that the poly (hydroxy acid) of average molecular mass of at least 20 000 is chosen from polymers and copolymers of alpha-hydroxy acids.  7. Process according to the preceding claim, characterized in that said poly (alpha-hydroxy acids) are chosen from poly (lactic acid) and poly (glycolic acid).  8. Method according to any one of claims 5 to 7, characterized in that the proportion of low molecular weight polymer, relative to the high molecular weight polymer, is sufficient to obtain microspheres having sufficiently small particle sizes desired.  9. Method according to the preceding claim, characterized in that said proportion may vary from 30 to 300% by weight, and in particular from 50 to 150% by weight.  10. A microsphere-based medicament as defined in any one of claims 1 to 4.